IDH1 and acute myeloid leukemia: Targeted therapy with IDH1/2 (isocitrate dehydrogenase1/2) or FLT3 (fms-related tyrosine kinase3) presents a promising treatment option for elderly AML patients who have specific mutation targets [13].